Abraxane Reps Will Number 100: Approval Of Novel Paclitaxel Formulation Expected In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
American Pharmaceutical Partners hopes to position metastatic breast cancer drug as superior to Taxol in safety, convenience and effectiveness. Parent company American Bioscience filed the NDA in early March and expects a priority review.